Detailed Narrative
Strong H1 FY20 Performance Driven by CRAMS
Suven Life Sciences reported robust H1 FY20 results, with income increasing by 62%, EBITDA by 115%, and net profit by 128% year-over-year. The strong Q2 performance saw total CRAMS revenue reach Rs. 206 crore, comprising Rs. 107 crore from commercial CRAMS, Rs. 54 crore from specialty chemicals, and Rs. 13 crore from technical services. Management cautioned that Q2 numbers included some ahead-of-schedule sales and should not be taken as a direct parameter for subsequent quarters, but overall business traction remains positive.
Commercial CRAMS and Specialty Chemicals Outlook
For the full year FY20, Suven expects commercial CRAMS revenue to be in the range of Rs. 170-190 crore, an upward revision from the earlier guidance of Rs. 160-170 crore. Specialty chemicals revenue is projected to reach around Rs. 210 crore, potentially up to Rs. 220 crore, with an anticipated growth of 5-10% from this base in subsequent years. The company maintains a general EBITDA margin guidance of 30-35%, with potential for higher margins from value-added products.
SUVN502 and SUVN3031 Pipeline Updates
A critical update was provided on SUVN502, with data lock completed and results expected within the next two to three weeks. The company has scheduled a presentation at CTAD 2019 (December 4-7 in San Diego) and plans to issue a press release as soon as results are available. For SUVN3031, a rare disease molecule, 8 patients have been randomized and over 20 are in the screening stage, with results anticipated by the end of next year. R&D spend for SUVN3031 is projected at $5 million for FY20 and $10 million overall, with an additional $5 million for SUVN502 closure payments.
CAPEX and Demerger Plans
Suven has a pending CAPEX of approximately Rs. 160 crore, with Rs. 100 crore expected to be spent in FY20 and Rs. 50 crore in FY21. This is in addition to a separate maintenance CAPEX of Rs. 30-40 crore annually. The occupational exposure level facility in Pashamylaram is expected to be commercialized this quarter, and an additional block in Vizag will be ready by end of Q3 next year. The demerger process is progressing, with the final NCLT hearing scheduled for November 29, 2019, and the demerger expected to be effective in January.
Rising Pharma Investment and ANDA Pipeline
Suven's investment in Rising Pharma is currently under US Bankruptcy Procedure, preventing full consolidation of financials. The company expects to consolidate profit (25% equivalent) once the bankruptcy process concludes and certified numbers are available, likely by the next quarter. Rising Pharma is expected to break even in 2021. In the ANDA pipeline, Suven has 8 filings (3 own, 5 with partner), with one already commercialized. The company anticipates 3-4 ANDAs to commercialize in calendar 2020, targeting a minimum of $2-3 million in revenue for Suven from these.
Taxation and FY21 Outlook
The company is currently applying the higher tax rate (33%+) and will decide on adopting the new reduced tax regime (25.17%) by March 31, 2020, post-demerger. For FY21, management provided guidance of 10-15% revenue growth and 20-25% bottom line growth, reflecting continued confidence in the core CRAMS business and pipeline progress. This outlook suggests a stable growth trajectory following the strong H1 performance.